The costs of Medicare associated with Sovaldi (sofosbuvir), an emerging hepatitis C drug, will vary depending on how many people are given the treatment, a blog in Health Affairs found.
The European Commission (EU) has granted Bristol-Myers Squibb’s Daklinza (daclatasvir) approval for an all-oral drug regimen for the treatment of four genotypes of chronic hepatitis C infection.
Surgeons transplanted a kidney from a donor who had hepatitis C to a recipient who also has the disease in what is believed to be the first of its kind in the state of Utah.
With the recent approval of new hepatitis C treatments, payers are increasingly concerned with controlling costs in this category through policies that may affect treatment decisions.
The United Kingdom’s National Institute for Health and Care Excellence (NICE) is recommending Solvaldi as a cost-effective option to treat some people who have chronic hepatitis C.
Between developing its own pipeline of therapies for patients with hepatitis C and acquiring another company known for its work in this field, it looks like Merck is taking steps to be a larger player in HCV market.